Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Novacyt    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 12/01 03:59:59 pm
8.425 EUR   -2.38%
11/16NOVACYT S.A. : ("Novacyt", the "Company" or the “Group”) R&D Update
BU
10/15NOVACYT S.A. : Acquisition of IT-IS International Ltd
BU
10/15NOVACYT : Acquisition
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Novacyt : RESULTS OF ANNUAL GENERAL MEETING

09/29/2020 | 12:25pm EST

RESULTS OF ANNUAL GENERAL MEETING

Paris, France and Cambridge, UK - 29 September 2020- Novacyt (EURONEXT GROWTH: ALNOV;

AIM: NCYT), an international specialist in clinical diagnostics, held today its Ordinary and Extraordinary General Meeting

The results of the AGM are set out in the table below, with the Company pleased to announce that all resolutions proposed to the shareholders were duly passed:

Resolutions

Votes For

Votes Against

Result

Number

%

Number

%

1)

Approval of the parent company

financial statements for the year

18,222,352

99.7890

38,532

0.2110

Adopted

ended 31 December 2019

2)

Approval

of

the

consolidated

18,222,352

99.7890

38,532

0.2110

financial statements for the year

Adopted

ended 31 December 2019

3)

Appropriation of the result for the

18,114,759

99.4131

106,940

0.5869

year ended 31 December 2019

Adopted

4)

Review

of

the

agreements

referred to in Articles L. 225-38et

18,163,387

99.7494

45,638

0.2506

Adopted

seq. of the French Commercial

Code

5)

Discharge

to the

Board

of

18,161,873

99.5460

82,827

0.4540

Adopted

Directors

6)

Authorisation

for

the

18,136,247

99.2048

145,379

0.7952

Company

to

buy

back

its

Adopted

own shares

7) Terms of

office

of

the

18,049,375

98.7764

223,580

1.2236

members

of

the

Board

of

Adopted

Directors

8) Terms of

office

of

the

18,212,985

99.7328

48,802

0.2672

Adopted

Statutory Auditors

9) Amount of remuneration allocated

to members

of

the

Board

of

17,821,689

98.1853

329,384

1.8147

Adopted

Directors for the year ended 31

December 2019

10)Amount

of remuneration

to

be

allocated

to

members

of

the

17,692,884

97.4987

453,914

2.5013

Adopted

Board of Directors from 1 January

2020

11)Powers for formalities

18,201,594

99.7658

42,721

0.2342

Adopted

Page 1 of 4

Resolutions

Votes For

Votes Against

Result

Number

%

Number

%

12)Amendment of Article 19 of the

18,139,274

99.3793

113,300

0.6207

Adopted

Company's Articles of Association

13)Delegation of authority granted to

the Board of Directors for the

purpose of allocating free shares,

16,534,574

90.8993

1,655,423

9.1007

existing or new, for the benefit of

Adopted

employees of the Company and of

related companies and corporate

officers

14)Delegation of authority granted to

the Board of Directors for the

purpose of granting options to

subscribe

for

and/or

purchase

shares of the Company, to

corporate officers and employees

16,178,893

88.7433

2,052,219

11.2567

Adopted

of the Company or of companies

in the group, involving the waiver

by

shareholders

of

their

preferential subscription right

to

shares

issued

following

the

exercise of subscription options

15)Overall limit on delegations

relating

to

free

shares

and

16,658,088

91.4780

1,551,848

8.5220

Adopted

subscription or purchase options

16)Delegation of authority to the

Board of Directors for the purpose

of issuing ordinary shares of the

Company

and/or

transferable

securities

giving

access to

the

15,210,240

83.4688

3,012,420

16.5312

Adopted

share capital of the Company,

with cancellation of shareholders'

preferential subscription rights in

favour of specific categories of

persons

17)Delegation of authority granted to

the Board of Directors for the

purpose of increasing the share

capital by issuing ordinary shares

or

securities

giving

access

to

16,186,881

88.9385

2,013,199

11.0615

ordinary shares to be issued by

Adopted

the Company immediately or in

the future in consideration for

contributions in kind within the

limit of 10% of the share capital,

except in the

case

of

a public

Page 2 of 4

Resolutions

Votes For

Votes Against

Result

Number

%

Number

%

exchange offer initiated by the

Company

18)Delegation of authority to the

Board of Directors for the purpose

of issuing ordinary shares and/or

transferable

securities

giving

15,263,457

83.8253

2,945,202

16.1747

immediate and/or deferred access

Adopted

to the capital of the Company,

with cancellation of shareholders'

preferential

subscription rights

and public offerings

19)Delegation of authority to the

Board of Directors for the purpose

of issuing ordinary shares of the

Company

and/or

transferable

16,683,635

91.5149

1,546,883

8.4851

Adopted

securities giving access to the

share capital of the Company,

with preferential

subscription

rights

20)Authorisation to the Board of

Directors, in the event of a capital

increase,

with

or

without

15,594,811

85.6974

2,602,713

14.3026

shareholders'

preferential

Adopted

subscription

rights,

to

increase

the number of securities to be

issued

21)Overall ceiling on delegations of

16,793,807

92.3175

1,397,549

7.6825

Adopted

authority

22)Delegation of authority to the

Board of Directors for the purpose

of issuing ordinary shares and/or

16,086,360

88.7152

2,046,221

11.2848

securities giving access to the

Adopted

Company's capital for the benefit

of members of a company savings

plan

23)Powers for formalities

18,177,470

99.7026

54,219

0.2974

Adopted

Number of participating shareholders (by voting form, proxy or present): 2,326 shareholders representing 18,345,785 shares.

- End -

Page 3 of 4

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer +44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

FTI Consulting (International) Victoria Foster Mitchell / Mary Whittow +44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com/ mary.whittow@fticonsulting.com

FTI Consulting (France) Arnaud de Cheffontaines +33 (0)147 03 69 48 arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

Page 4 of 4

Disclaimer

Novacyt SA published this content on 29 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 September 2020 16:24:09 UTC


© Publicnow 2020
All news about NOVACYT
11/16NOVACYT S.A. : ("Novacyt", the "Company" or the “Group”) R&D Update
BU
10/15NOVACYT S.A. : Acquisition of IT-IS International Ltd
BU
10/15NOVACYT : Acquisition
CO
09/29NOVACYT : Results of annual general meeting
PU
09/29NOVACYT S.A. :  New Contract With UK DHSC for Instrument Platforms and COVID-19 ..
BU
09/29NOVACYT : S.A. ("Novacyt :" or the "Company") Launch of COVID-19 Antibody Test
BU
09/17NOVACYT : Interim Accounts June 2020
PU
09/17NOVACYT : Rapport D'Activitie Semestriel 2020
PU
09/17NOVACYT S.A. ("NOVACYT", THE "COMPAN : Half Year 2020 Results
BU
09/17NOVACYT : Half-year results
CO
More news
Financials
Sales 2020 296 M 357 M 357 M
Net income 2020 180 M 217 M 217 M
Net cash 2020 6,85 M 8,25 M 8,25 M
P/E ratio 2020 3,34x
Yield 2020 -
Capitalization 609 M 728 M 734 M
EV / Sales 2020 2,03x
EV / Sales 2021 1,80x
Nbr of Employees 110
Free-Float 99,3%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 14,14 €
Last Close Price 8,52 €
Spread / Highest target 71,7%
Spread / Average Target 66,0%
Spread / Lowest Target 60,2%
EPS Revisions
Managers
NameTitle
Graham David Mullis Chief Executive Officer & Executive Director
James Christopher Wakefield Chairman
Lisa Henriet Director-Group Operations
Anthony Dyer CFO, Secretary & Executive Director
Jean-Pierre Crinelli Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVACYT5,006.51%728
GILEAD SCIENCES, INC.-6.63%76 052
MODERNA, INC.680.88%60 441
VERTEX PHARMACEUTICALS4.02%59 224
REGENERON PHARMACEUTICALS37.43%54 464
LONZA GROUP AG61.27%46 692